MANDATORY NOTIFICATION OF TRADE AND DISCLOSURE OF LARGE SHAREHOLDING

Chairman of the Board and Primary Insider, Frode Marc Bohan, has on 29th December 2019 reduced the number of shares he controls in NattoPharma ASA from 3 646 429 shares, representing 20,1% of the outstanding shares, to 2 572 746 shares, representing 14,15% of the outstanding shares.

The above reduction is a result of a transaction whereby Mr. Bohan’s company Bohan & Co AS has sold its shares in TG Montgomery AS to ImmunoPharma AS. Previous to the transaction, Mr. Bohan controlled 1 735 122 shares in NattoPharma ASA via TG Montgomery AS. Following the transaction, this is reduced to 661 169 shares in NattoPharma ASA which Mr. Bohan controls via his shareholdings in Nxt Capital Ltd and Bohan & Co AS and their respective shareholdings in ImmunoPharma AS, as well as the shareholding of his related party Patrycja Ratusinska in ImmunoPharma AS.

Frode Marc Bohan will, directly and indirectly through Bohan & Co AS (1 098 455 shares), ImmunoPharma AS (661 169 shares), NxT Capital Ltd (452 852 shares) and the related parties Patrycja Ratusinska (350 000 shares), Stella Bohan (10,000 shares) and Alexander Rye Bohan-Ellingensen (10 000 shares, not yet transferred from Bohan & Co AS), control 2 572 746 shares in NattoPharma ASA, representing 14,15% of the outstanding shares. Mr. Bohan also holds 150 000 options in the company.

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.

Subscribe

Documents & Links